<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104193</url>
  </required_header>
  <id_info>
    <org_study_id>PH CL 25</org_study_id>
    <nct_id>NCT02104193</nct_id>
  </id_info>
  <brief_title>Simvastatin Effect on Radiation Therapy of Brain Metastases</brief_title>
  <official_title>The Effect of Simvastatin on the Clinical Outcome of Patients With Brain Metastases Treated With Radiation Therapy: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of simvastatin in combination with
      radiotherapy on the clinical outcomes of patients with brain metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite current advances in therapies, the outcome for patients with brain metastases is
      fatal. New therapeutic approaches, such as radiosensitizing agents, are needed to provide a
      significant survival advantage for those patients. Statins have been reported to enhance the
      efficacy of radiotherapy in addition to a neuroprotective effect. The aim of the study is to
      evaluate the effect of simvastatin on the efficacy and safety of radiation therapy in
      patients with brain metastases and on improving patients' quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a- Response rate</measure>
    <time_frame>4 weeks after radiation therapy</time_frame>
    <description>brain CT/MRI will be done at baseline and 4 weeks after radiotherapy to evaluate the reduction in tumor size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free and overall survival</measure>
    <time_frame>up to 6 months</time_frame>
    <description>it measures time from treatment initiation to either progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>during the treatment period</time_frame>
    <description>any adverse/side effect will be evaluated</description>
  </secondary_outcome>
  <other_outcome>
    <measure>quality of life</measure>
    <time_frame>baseline, after radiation therapy, 6 weeks, 18 weeks, 30 weeks</time_frame>
    <description>measures the patient quality of life</description>
  </other_outcome>
  <other_outcome>
    <measure>cognitive function assessment using Montreal cognitive assessment test</measure>
    <time_frame>baseline, after radiation therapy, 6 weeks, 18 weeks, 30 weeks</time_frame>
    <description>assess the patient cognitive function by the evaluation of Montreal cognitive assessment test score</description>
  </other_outcome>
  <other_outcome>
    <measure>serum s100 B protein</measure>
    <time_frame>baseline, after radiation therapy</time_frame>
    <description>evaluate serum s100 B protein at baseline and after 2 weeks</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>they will receive simvastatin in addition to radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>they will receive radiation therapy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin in addition to radiation therapy</intervention_name>
    <description>simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks</description>
    <arm_group_label>simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>radiation therapy 30 Gy delivered in 10 fractions over 2 weeks</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with measurable brain metastases

          -  Age more than 18 years old

          -  Patients should be planned for radiation therapy

        Exclusion Criteria:

          -  Renal dysfunction (more than 1 upper normal level)

          -  Hepatic dysfunction (alanine aminotransferase (ALT) and/or aspartate aminotransferase
             (AST) &gt;3 times the upper normal level )

          -  Pregnancy or lactation.

          -  Known hypersensitivity to simvastatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>May A Shawki, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Pharmacy- Ain Shams university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams university Hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>MAy Ahmed Shawki</investigator_full_name>
    <investigator_title>teaching assisstant</investigator_title>
  </responsible_party>
  <keyword>brain metastases</keyword>
  <keyword>simvastatin</keyword>
  <keyword>radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

